TITLE

Comparative dose-response study of three anticholinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease

AUTHOR(S)
Ikeda, A; Nishimura, K; Koyama, H; Izumi, T
PUB. DATE
January 1995
SOURCE
Thorax;Jan1995, Vol. 50 Issue 1, p62
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
66023122

 

Related Articles

  • A Review of Ipratropium Bromide/Fenoterol Hydrobromide (Berodual®) Delivered Via Respimat® Soft Mistâ„¢ Inhaler in Patients with Asthma and Chronic Obstructive Pulmonary Disease. Kässner, Frank; Hodder, Rick; Bateman, Eric D. // Drugs;2004, Vol. 64 Issue 15, p1671 

    Asthma and chronic obstructive pulmonary disease (COPD) can be effectively treated by the use of bronchodilator therapies delivered by inhalation. Berodual® is a fixed combination of the anticholinergic agent ipratropium bromide (IB) and the β2-adrenergic agonist fenoterol hydrobromide...

  • Tiotropium for uncontrolled asthma.  // Neurology Alert;Dec2010 Supplement, p1 

    The article focuses on a study which investigated the therapeutic use of tiotropium, a long-acting anticholinergic inhaler, for patients with chronic obstructive pulmonary disease (COPD).

  • Safety of Inhaled Anticholinergics for COPD Scrutinized.  // Internal Medicine Alert;10/29/2008 Pharmacology Watch, Vol. 30, p1 

    The article discusses the medical study which investigates the effects of inhaled anticholinergics by patients with chronic obstructive pulmonary disease (COPD).

  • Ipratropium and cardiovascular events in COPD.  // Internal Medicine Alert;3/15/2010, Vol. 32 Issue 5, p39 

    The article discusses the risk on the use of metered-dose inhaler administration of ipratropium (IPR) among patients with chronic obstructive pulmonary disease (COPD).

  • COPD Inhaler Selection - Factors to Consider. Straw, Andrew; Heins, Jodi R.; Evers, Meredith // South Dakota Medicine;May2015, Vol. 68 Issue 5, p217 

    The article discusses the factors to be considered while selecting inhalers for the treatment of chronic obstructive pulmonary disease (COPD). Topics discussed include consideration of the patient's adherence to the device, availability of different types of inhalers such as dry powder inhalers,...

  • Inhaled anticholinergics for COPD. Tanzi, Maria G. // Pharmacy Today;Dec2008, Vol. 14 Issue 12, p23 

    The article presents a study concerning the effectiveness of the inhaled anticholinergics for chronic obstructive pulmonary disease (COPD) treatment. Research shows that anticholinergics such as ipratropium and tiotropium were associated with increased risk for cardiovascular death in patients...

  • Combined Inhaled Bronchodilators in COPD. Miller, Karl E. // American Family Physician;8/15/2001, Vol. 64 Issue 4, p661 

    Presents information on a study by S. Benayoun and others on the impact of combined inhaled bronchodilators in the treatment of chronic obstructive pulmonary disease (COPD). Description of the study and its results; Conclusion that using the combined ipratropium and beta2 agonist metered-dose...

  • ANTICHOLINERGIC AGENTS INCREASE SOME RISKS FOR COPD PATIENTS. MULLETT, STEVE // RN;Nov2008, Vol. 71 Issue 11, p23 

    The article discusses research being done on the impact of anticholinergic agents on patients diagnosed with chronic obstructive pulmonary disease (COPD). It references a study by Sonal Singh and colleagues, published in the September 24, 2008 issue of the "Journal of the American Medical...

  • Pharmacological Treatment in Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Ikeda, A.; Nishimura, K.; Izumi, T. // Drugs & Aging;1998, Vol. 12 Issue 2, p129 

    Exacerbations of chronic obstructive pulmonary disease (COPD) are usually treated with bronchodilator therapy, glucocorticoids and antibiotics. However, there are few experimental data on the effects of these agents in patients with acute COPD. A β-adrenoceptor agonist is usually given first...

  • Review: Inhaled anticholinergics increase risk for major cardiovascular events in chronic obstructive pulmonary disease.  // Einstein (16794508);Jan2010, Vol. 8 Issue 1, Special section p24 

    The article examines various studies that explores if inhaled anticholinergics can increase risks of major cardiovascular events in patients with chronic obstructive pulmonary disease (COPD). The scope involves studies that compared an inhaled anticholinergic with placebo or active drugs in...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics